和黄医药宣布索凡替尼在华新药申请获受理 纳入优先审评与突破性治疗品种

美股速递
Apr 29

和黄医药今日宣布,其创新药物索凡替尼(Sovlepenib)的新药申请(NDA)已获得中国国家药品监督管理局正式受理,并被同时纳入优先审评程序与突破性治疗品种目录。这一重要进展标志着该药物在中国商业化进程中迈出关键一步,有望为相关疾病领域患者提供新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10